10 Best Small Cap Stocks to Buy Now - 10 of 10 Slide 10Back to 9Next Slideshow Back to 9Next Slideshow Enliven Therapeutics (NASDAQ:ELVN)Consensus Rating BuyRating Score 3.3Ratings Breakdown 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.Consensus Price Target $34.33 (48.1% Upside)About Enliven TherapeuticsEnliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. Read More Recent Analyst RatingsDateBrokerageActionRatingPrice TargetDetails9/9/2024HC WainwrightInitiated CoverageBuy$37.006/11/2024Baird R WUpgradeStrong-Buy6/11/2024Robert W. BairdInitiated CoverageOutperform$32.004/9/2024MizuhoInitiated CoverageBuy$34.003/29/2023Jefferies Financial GroupInitiated CoverageBuy$27.003/7/2023Lifesci CapitalReiterated RatingOutperform3/3/2023TD CowenInitiated CoverageOutperformMore Investing Slideshows:7 Undervalued Growth Stocks Ready for Reversal7 ETFs to Invest in Now for Maximum Returns7 Low Beta Stocks for the Risk-Averse Investor7 Best REITs to Buy as the Interest Rates Fall7 Best Stocks Under $5 to Buy Now7 Consumer Discretionary Stocks That Will Heat Up with Rate Cuts 7 of the Best Options for Investing $5,000 in 20257 Energy Stocks with Attractive High-Yield Dividends7 Stocks That Can Help You Cash In on the GLP-1 Revolution7 Industrial Stocks with Safe, Growing DividendsSlide 10Back to 9Next Slideshow How the US Will Win the Great Lithium Race (Ad)China spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but it processes 70-80%. Now the US is coming over the top by investing $700B+ into domestic supply with the IRA and Bi-partisan Infrastructure Bill.Join GM as an early investor in this company by October 3.More From MarketBeatHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | Sponsored7 Oversold Stocks That Could Be Setting Up for a RallyIn 2024, investors are still wrestling with uncertainty. Will there be rate cuts, and what will they mean for ...MarketBeatThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredThe Best Energy Stocks to Buy NowWith recent disruptions in the international energy markets, there has been a renewed attention on public ener...MarketBeatAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | Sponsored7 Downgraded Stocks That Still May Be Worth a LookA key reason a stock price drops is one or more analyst downgrades. An analyst typically downgrades a stock be...MarketBeat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Slide 10Back to 9Next Slideshow Back to 9Next Slideshow Enliven Therapeutics (NASDAQ:ELVN)Consensus Rating BuyRating Score 3.3Ratings Breakdown 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.Consensus Price Target $34.33 (48.1% Upside)About Enliven TherapeuticsEnliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. Read More Recent Analyst RatingsDateBrokerageActionRatingPrice TargetDetails9/9/2024HC WainwrightInitiated CoverageBuy$37.006/11/2024Baird R WUpgradeStrong-Buy6/11/2024Robert W. BairdInitiated CoverageOutperform$32.004/9/2024MizuhoInitiated CoverageBuy$34.003/29/2023Jefferies Financial GroupInitiated CoverageBuy$27.003/7/2023Lifesci CapitalReiterated RatingOutperform3/3/2023TD CowenInitiated CoverageOutperformMore Investing Slideshows:7 Undervalued Growth Stocks Ready for Reversal7 ETFs to Invest in Now for Maximum Returns7 Low Beta Stocks for the Risk-Averse Investor7 Best REITs to Buy as the Interest Rates Fall7 Best Stocks Under $5 to Buy Now7 Consumer Discretionary Stocks That Will Heat Up with Rate Cuts 7 of the Best Options for Investing $5,000 in 20257 Energy Stocks with Attractive High-Yield Dividends7 Stocks That Can Help You Cash In on the GLP-1 Revolution7 Industrial Stocks with Safe, Growing DividendsSlide 10Back to 9Next Slideshow How the US Will Win the Great Lithium Race (Ad)China spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but it processes 70-80%. Now the US is coming over the top by investing $700B+ into domestic supply with the IRA and Bi-partisan Infrastructure Bill.Join GM as an early investor in this company by October 3.More From MarketBeatHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | Sponsored7 Oversold Stocks That Could Be Setting Up for a RallyIn 2024, investors are still wrestling with uncertainty. Will there be rate cuts, and what will they mean for ...MarketBeatThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredThe Best Energy Stocks to Buy NowWith recent disruptions in the international energy markets, there has been a renewed attention on public ener...MarketBeatAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | Sponsored7 Downgraded Stocks That Still May Be Worth a LookA key reason a stock price drops is one or more analyst downgrades. An analyst typically downgrades a stock be...MarketBeat
